Get the Stockscreener App
12.88
0.63%
0.08
Neogenomics Inc stock is traded at $12.88, with a volume of 117.31K.
It is up +0.63% in the last 24 hours and up +8.24% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$12.80
Open:
$12.82
24h Volume:
117.31K
Relative Volume:
0.04
Market Cap:
$1.67B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-20.77
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
+9.52%
1M Performance:
+8.24%
6M Performance:
+76.20%
1Y Performance:
-29.85%
1-Day Range:
$12.80
$13.05
1-Week Range:
$11.41
$13.05
52-Week Range:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
12.88 | 1.66B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
621.03 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.80 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
716.95 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.81 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
243.25 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
A Look At NeoGenomics (NEO) Valuation After Recent Share Price Momentum Shift - Yahoo Finance
NeoGenomics, Inc. (NEO) Investor Outlook: Diagnostic Leader With 18% Upside Potential - DirectorsTalk Interviews
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The AI Journal
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
NeoGenomics Adds Diagnostics Executive Jack Kenny To Board - Pulse 2.0
HighMark Wealth Management LLC Has $3.09 Million Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics Announces Board Changes to Support Future Growth - The Globe and Mail
NeoGenomics appoints diagnostics veteran Jack Kenny to board By Investing.com - Investing.com Nigeria
NeoGenomics, Inc. (NEO) Stock Analysis: Exploring a 13% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
NeoGenomics appoints diagnostics veteran Jack Kenny to board - Investing.com
Neogenomics appoints diagnostics and lab services industry veteran John P. "Jack" Kenny to its board of directors - marketscreener.com
NeoGenomics Announces Board Changes - TradingView — Track All Markets
Neogenomics Appoints Diagnostics And Lab Services Industry Veteran John P. “Jack” Kenny To Its Board Of Directors - TradingView — Track All Markets
NeoGenomics, Inc. Announces Resignation of Dr. Alison L. Hannah as a Director, Effective December 31, 2025 - marketscreener.com
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors - The Joplin Globe
NeoGenomics to Build State-of-the-Art Oncology Laboratory and Global Headquarters in Fort Myers, Florida - ACCESS Newswire
NeoGenomics, Inc. $NEO Shares Sold by Kopp Family Office LLC - MarketBeat
Does NeoGenomics (NASDAQ:NEO) Have A Healthy Balance Sheet? - 富途牛牛
Is NeoGenomics Inc. (NG9) stock a safe buy pre earnings2025 Earnings Surprises & Safe Swing Trade Setups - Улправда
Will NeoGenomics Inc. (NG9) stock outperform foreign stocks2025 Sector Review & Free Risk Controlled Daily Trade Plans - Bölüm Sonu Canavarı
How rising interest rates impact NeoGenomics Inc. stock2025 Price Momentum & Trade Opportunity Analysis - Улправда
Will NeoGenomics Inc. stock benefit from infrastructure spendingMarket Sentiment Report & Real-Time Market Trend Scan - DonanımHaber
Can NeoGenomics Inc. (NG9) stock sustain margin levelsCPI Data & Trade Opportunity Analysis Reports - Улправда
Should NeoGenomics’ Cleared RaDaR Patent Overhang and New Data Shift the NEO Investment Narrative? - Sahm
Will NeoGenomics Inc. stock continue dividend increasesJuly 2025 Gainers & Precise Swing Trade Entry Alerts - Улправда
Pathological Examination Market set to strong growth with a CAGR - openPR.com
Natera dismisses appeal in patent case against NeoGenomics By Investing.com - Investing.com Australia
Millennium Management LLC Acquires Additional Shares in NeoGenomics Inc - GuruFocus
Natera dismisses appeal in patent case against NeoGenomics - Investing.com India
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litig - pharmiweb.com
NeoGenomics Says Natera Withdraws Appeal in Patent Case - marketscreener.com
Neogenomics announces that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation - marketscreener.com
Neogenomics Announces That Natera Has Voluntarily Withdrawn Its Appeal In Ongoing RaDaR Patent Litigation - TradingView — Track All Markets
NeoGenomics, Inc. $NEO Shares Acquired by Squarepoint Ops LLC - MarketBeat
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Yahoo Finance
Value Recap: Will NeoGenomics Inc NG9 stock outperform foreign stocksJuly 2025 Retail & AI Enhanced Execution Alerts - moha.gov.vn
US Market Wrap: Why NeoGenomics Inc stock is trending among retail tradersJuly 2025 Summary & Safe Entry Point Identification - moha.gov.vn
Bellevue Group AG Reduces Stake in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics Inc Stock Analysis and ForecastTake Profit Strategies & Start Your Free Trading Journey Today - earlytimes.in
What analysts say about The Hershey Company stockShort Interest Overview & Free Long-Term Investment Planning - earlytimes.in
The Supreme Industries Limited (SUPREMEIND) Announces Strategic ShiftValue Traps to Avoid & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Will New RaDaR MRD Data and Myeloid Profiling Advances Change NeoGenomics' (NEO) Diagnostics Narrative? - simplywall.st
NeoGenomics to Present New ctDNA Research at SABCS 2025 - BioSpace
NeoGenomics (NEO): Assessing Valuation After a 44% Three-Month Share Price Rebound - Yahoo Finance
Quantbot Technologies LP Buys New Holdings in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - BioSpace
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):